Drug Trial Radar · NCT06298071
A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Mar 3, 2023
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Shanghai Institute Of Biological ProductsIndustry
- Sponsor type
- Industry
- Collaborators
- The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Henan University of Science and Technology
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.
Conditions
- Gout
Interventions
SIBP-R002Drug
Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
SIBP-R002Drug
Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
SIBP-R002Drug
Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
MethotrexateDrug
Combination drugs: Methotrexate, dose15 mg, oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AE(Adverse Events)Time frame: 14 weeks after the first dose
- SAE(Serious Adverse Events)Time frame: 14 weeks after the first dose
- AUC(Area Under The Plasma Concentration Versus Time Curve)Time frame: 14 weeks after the first dose
- Cmax(Peak Plasma Concentration)Time frame: 14 weeks after the first dose
- Tmax(Peak Time)Time frame: 14 weeks after the first dose
- T ½ (Terminal elimination half-life)Time frame: 14 weeks after the first dose
- CL (Clearance Rate)Time frame: 14 weeks after the first dose
- ADA (Anti-uricase Antibody, Anti-PEG Antibody, Anti-PEG-uricase Antibody)Time frame: 14 weeks after the first dose
- NAb (Anti-PEG-uricase Neutralizing Antibody)Time frame: 14 weeks after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.